<li>acarbose<p>trazodone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>almotriptan<p>trazodone, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>alvimopan<p>trazodone will decrease the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>ambenonium<p>ambenonium increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>amobarbital<p>amobarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>anticholinergic/sedative combos<p>anticholinergic/sedative combos and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>armodafinil<p>trazodone will decrease the level or effect of armodafinil by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>atorvastatin<p>trazodone increases levels of atorvastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>atropine<p>atropine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.<span><br><br></span>trazodone increases levels of atropine by unknown mechanism. Minor/Significance Unknown.</p></li><li>atropine iv/im<p>trazodone increases levels of atropine iv/im by unknown mechanism. Minor/Significance Unknown.</p></li><li>bazedoxifene/conjugated estrogens<p>bazedoxifene/conjugated estrogens, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>belladonna alkaloids<p>belladonna alkaloids and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>benztropine<p>benztropine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>bethanechol<p>bethanechol increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>brimonidine<p>trazodone decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>bumetanide<p>bumetanide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>butabarbital<p>butabarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>butalbital<p>butalbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>carbachol<p>carbachol increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>carbamazepine<p>carbamazepine decreases levels of trazodone by increasing metabolism. Minor/Significance Unknown.</p></li><li>celandine<p>celandine decreases effects of trazodone by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.</p></li><li>cevimeline<p>cevimeline increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>chlorpromazine<p>trazodone, chlorpromazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, chlorpromazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>chlorpropamide<p>trazodone increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>cisatracurium<p>cisatracurium and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>conjugated estrogens<p>conjugated estrogens, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>conjugated estrogens, vaginal<p>conjugated estrogens, vaginal, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>cyclizine<p>cyclizine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>cyclobenzaprine<p>cyclobenzaprine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>darifenacin<p>darifenacin and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>desflurane<p>desflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of trazodone by decreasing metabolism. Minor/Significance Unknown.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dicyclomine<p>dicyclomine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>diltiazem<p>diltiazem increases levels of trazodone by decreasing metabolism. Minor/Significance Unknown.</p></li><li>diphenhydramine<p>diphenhydramine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>donepezil<p>donepezil increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>echothiophate iodide<p>echothiophate iodide increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>edrophonium<p>edrophonium increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>eletriptan<p>trazodone, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>enflurane<p>enflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>estradiol<p>estradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estrogens conjugated synthetic<p>estrogens conjugated synthetic, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estrogens esterified<p>estrogens esterified, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estropipate<p>estropipate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>ethacrynic acid<p>ethacrynic acid, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>ethanol<p>ethanol, trazodone.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.</p></li><li>ethinylestradiol<p>ethinylestradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.</p></li><li>ethotoin<p>trazodone increases levels of ethotoin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>etomidate<p>etomidate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>eucalyptus<p>trazodone and eucalyptus both increase  sedation. Minor/Significance Unknown.</p></li><li>fesoterodine<p>fesoterodine and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>fexofenadine<p>trazodone will decrease the level or effect of fexofenadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>flavoxate<p>flavoxate and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>fluphenazine<p>trazodone, fluphenazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, fluphenazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>fosphenytoin<p>trazodone increases levels of fosphenytoin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>frovatriptan<p>trazodone, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>furosemide<p>furosemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>galantamine<p>galantamine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>glimepiride<p>trazodone increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glipizide<p>trazodone increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>gliquidone<p>trazodone increases effects of gliquidone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glyburide<p>trazodone increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glycopyrrolate<p>glycopyrrolate and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>glycopyrrolate inhaled<p>glycopyrrolate inhaled and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.<span><br><br></span>trazodone increases levels of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.</p></li><li>hexobarbital<p>hexobarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>hydroxyprogesterone caproate<p>hydroxyprogesterone caproate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>insulin aspart<p>trazodone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin detemir<p>trazodone increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin glargine<p>trazodone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin glulisine<p>trazodone increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin lispro<p>trazodone increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin nph<p>trazodone increases effects of insulin nph by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin regular human<p>trazodone increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>isoproterenol<p>isoproterenol, trazodone. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.</p></li><li>ketamine<p>ketamine, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>lithium<p>lithium, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of neurotoxicity in geriatric pts.  Multiple mechanisms involved.<span><br><br></span>trazodone, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.</p></li><li>loratadine<p>trazodone will decrease the level or effect of loratadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>lovastatin<p>trazodone increases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>mephobarbital<p>mephobarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>mestranol<p>mestranol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>metformin<p>trazodone increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of trazodone by decreasing metabolism. Minor/Significance Unknown.</p></li><li>miglitol<p>trazodone increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>naratriptan<p>trazodone, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>nateglinide<p>trazodone increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>neostigmine<p>neostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>onabotulinumtoxina<p>onabotulinumtoxina and trazodone both decrease  cholinergic effects/transmission. Minor/Significance Unknown.</p></li><li>panax ginseng<p>panax ginseng increases effects of trazodone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>pentobarbital<p>pentobarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>perphenazine<p>trazodone, perphenazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, perphenazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>phenobarbital<p>phenobarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>phenytoin<p>trazodone increases levels of phenytoin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>physostigmine<p>physostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>pilocarpine<p>pilocarpine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>pilocarpine ophthalmic<p>pilocarpine ophthalmic increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>pioglitazone<p>trazodone increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>pitavastatin<p>trazodone increases levels of pitavastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of trazodone by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>pravastatin<p>trazodone increases levels of pravastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>primidone<p>primidone, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>prochlorperazine<p>trazodone, prochlorperazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, prochlorperazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>progesterone micronized<p>progesterone micronized, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>promazine<p>trazodone, promazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, promazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>promethazine<p>trazodone, promethazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, promethazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>propofol<p>propofol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>pyridostigmine<p>pyridostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>repaglinide<p>trazodone increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>rivastigmine<p>rivastigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>rizatriptan<p>trazodone, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>rosiglitazone<p>trazodone increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>rosuvastatin<p>trazodone increases levels of rosuvastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>ruxolitinib<p>trazodone will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>sage<p>trazodone and sage both increase  sedation. Minor/Significance Unknown.</p></li><li>saxagliptin<p>trazodone increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>secobarbital<p>secobarbital, trazodone. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>sevoflurane<p>sevoflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>simvastatin<p>trazodone increases levels of simvastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sitagliptin<p>trazodone increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>succinylcholine<p>succinylcholine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>sulfamethoxazole<p>sulfamethoxazole decreases levels of trazodone by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sumatriptan<p>trazodone, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan intranasal<p>trazodone, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan transdermal<p>trazodone, sumatriptan transdermal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>tacrine<p>tacrine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>thioridazine<p>trazodone, thioridazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, thioridazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>tolazamide<p>trazodone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>tolbutamide<p>trazodone increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>torsemide<p>torsemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>trifluoperazine<p>trazodone, trifluoperazine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.<span><br><br></span>trazodone, trifluoperazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>troglitazone<p>trazodone increases effects of troglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>vasopressin<p>trazodone increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>verapamil<p>verapamil increases levels of trazodone by decreasing metabolism. Minor/Significance Unknown.</p></li><li>vildagliptin<p>trazodone increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zolmitriptan<p>trazodone, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>zolpidem<p>zolpidem, trazodone.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.</p></li>